Balchem Corporation

Balchem Corporation(BCPC)の株式分析

$178.440

+0.589 (+0.33%)終値時点

Loading chart…
High
180.290
Open
178.970
VWAP
178.60
Vol
150.71K
Mkt Cap
4.92B
Low
177.073
Amount
26.92M
EV/EBITDA, TTM
19.42

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

balchem.com

AI analysis of Balchem Corporation (BCPC)

buy

Balchem Corp appears to be a good buy right now due to its recent performance and growth potential. The current price is $178.44, and the company reported a Q2 non-GAAP EPS of $1.49, exceeding expectations by $0.06. Additionally, the forward P/E ratio is 32.36, indicating growth potential relative to earnings. The main risk is the insider selling, which has increased by 1060.90% over the last month, suggesting some caution from insiders.

バリュエーション指標

The current forward P/E ratio for Balchem Corporation (BCPC) is 32.36, compared to its 5-year average forward P/E of 32.83.

Forward P/E

Fair
5Y Average P/E
32.83
Current P/E
32.36
割高
36.21
割安
29.46

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
20.70
Current EV/EBITDA
19.42
割高
22.83
割安
18.57

Forward P/S

Fair
5Y Average P/S
4.81
Current P/S
4.74
割高
5.41
割安
4.21

Alphio AI Price Scenarios for BCPC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BCPC

$162.17

シナリオ価格

B

Base

Base · 50%BCPC

$159.96

シナリオ価格

B

Bear

Bear · 25%BCPC

$150.29

シナリオ価格

Whales holding BCPC

S

Salem Investment Counselors, Inc.

+ HoldingBCPC

+0.74%

3M Return

A

Algert Global LLC

+ HoldingBCPC

-4.08%

3M Return

イベントタイムライン

2026-07-31 (ET)

07:31:00

Balchem Reports Q2 Revenue of $284M

2026-04-30 (ET)

07:50:00

Balchem Q1 Revenue $270.71M Beats Consensus

2026-03-09 (ET)

08:20:00

Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform

2026-02-20 (ET)

07:20:00

Balchem Reports Q4 Revenue of $263.6M

2025-12-22 (ET)

08:10:00

Eastman and Balchem Welcome EU's Anti-Dumping Duties on Choline Chloride Imports from China

ニュース

BCPC FAQ — answered by Alphio AI

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).

Balchem Corp appears to be a good buy right now due to its recent performance and growth potential. The current price is $178.44, and the company reported a Q2 non-GAAP EPS of $1.49, exceeding expectations by $0.06. Additionally, the forward P/E ratio is 32.36, indicating growth potential relative to earnings. The main risk is the insider selling, which has increased by 1060.90% over the last month, suggesting some caution from insiders.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める